

SUPPLEMENTAL MATERIAL

Supplemental figures

- **Fig. S1.** *MAB_2299c* PCR amplicons from *M. abscessus* isolates with reduced susceptibility to clofazimine and bedaquiline.
- **Fig. S2.** Concentration-ranging bactericidal activity of bedaquiline with imipenem/avibactam combinations against *M. abscessus* ATCC 19977 WT parent and OM7 mutant strains.
- **Fig. S3.** Relative ATP levels, not adjusted by CFU counts, associated with exposure of *M. abscessus* ATCC 19977 WT to bedaquiline and imipenem for 1 day or 3 days in CAMHB with 0.05% Tween 80.
- **Fig. S4.** Activity of bedaquiline and imipenem against *M. abscessus* ATCC 19977 WT, with CFU-adjusted and unadjusted relative bacterial ATP levels, in CAMHB without Tween 80.
- **Fig. S5.** Relative ATP levels, not adjusted by CFU counts, associated with exposure of *M. abscessus* ATCC 19977 WT and OM7 mutant to bedaquiline and imipenem for 1 day or 3 days in CAMHB without Tween 80.
- **Fig. S6.** Activity of bedaquiline and imipenem against nutrient-starved *M. abscessus* ATCC 19977 WT and OM7 mutant, with relative bacterial ATP levels, in PBS without Tween 80.
- **Fig. S7.** Relative ATP levels, not adjusted by CFU counts, associated with exposure of nutrient-starved *M. abscessus* ATCC 19977 WT to bedaquiline and imipenem for 4 hours, 1 day, 3 days, or 7 days in PBS without Tween 80.
- **Fig. S8.** Relative ATP levels, not adjusted by CFU counts, associated with exposure of nutrient-starved *M. abscessus* OM7 mutant to bedaquiline and imipenem for 4 hours, 1 day, 3 days, or 7 days in PBS without Tween 80.
- **Fig. S9.** Activity of bedaquiline and imipenem against nutrient-starved *M. abscessus* ATCC 19977 WT in PBS with 0.05% Tween 80.
- **Fig. S10.** Activity of bedaquiline and imipenem against nutrient-starved *M. abscessus* ATCC 19977 WT in PBS without Tween 80 and with 0.05% Tween 80.
- **Fig. S11.** Concentration-ranging activity of bedaquiline and imipenem alone against intracellular (THP-1 cells) *M. abscessus* ATCC 19977 WT.

Supplemental tables

- **Table S1.** Bedaquiline-resistant *M. abscessus* laboratory isolates.
- **Table S2.** CFU data from samples presented in Fig. 1.
- **Table S3.** CFU data from samples presented in Fig. 2.
- **Table S4.** CFU data from samples presented in Fig. S2.
- **Table S5.** CFU data from samples presented in Fig. 3.
- **Table S6.** CFU and relative light unit data from samples presented in Fig. 4 and Fig. S3.
- **Table S7.** CFU data from samples presented in Fig. 5.
- **Table S8.** CFU and relative light unit data from samples presented in Fig. 6 and Fig. S5.
- **Table S9.** CFU and relative light unit data from samples presented in Fig. S4.
- **Table S10.** CFU and relative light unit data from samples presented in Fig. 7, Fig. S6, Fig. S7, and Fig. S8.
- **Table S11.** CFU data from samples presented in Fig. 8 and Fig. S9.
- **Table S12.** CFU data from samples presented in Fig. S10.
- **Table S13.** CFU data from intracellular samples presented in Fig. 9 and Fig. S11.




Fig. S1. *MAB_2299c* PCR amplicons from *M. abscessus* isolates with reduced susceptibility to clofazimine and bedaquiline. The expected amplicon size for the *M. abscessus* ATCC 19977 WT parent strain was 796 bp.




Fig. S2. Concentration-ranging bactericidal activity of bedaquiline with imipenem (IPM)/avibactam (AVI) combinations against *M. abscessus* ATCC 19977 WT parent (A) and OM7 mutant (B) strains. The change in log₁₀ CFU/mL after 3 days of drug exposure relative to Day 0 is presented for each drug/strain set. Assay medium was CAMHB with 0.05% Tween 80. The number after each IPM and AVI abbreviation represents the concentration µg/mL. The Day 0 bacterial concentrations were 6.13 and 6.22 log₁₀ CFU/mL for WT and OM7 mutant strains, respectively. CFU values are provided in **Table S4**.




Fig. S3. Relative ATP levels, not adjusted by CFU counts, associated with exposure of *M. abscessus* ATCC 19977 WT to bedaquiline (BDQ) and imipenem (IPM) for 1 day (A,B) or 3 days (C,D) in CAMHB with 0.05% Tween 80. Replicate 1 (A,C) is the experiment presented in Fig. 4A,C. Replicate 2 (B,D) is the experiment presented in Fig. 4B,D. ATP levels are indicated by relative light units (RLU)/CFU from samples. Black bars represent the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM plus BDQ samples. The number after each drug abbreviation represents the concentration in $\mu\text{g/mL}$ (for gray bars the BDQ concentration in $\mu\text{g/mL}$ is presented under each bar). RLU values are provided in Table S6.




Fig. S4. Activity of bedaquiline (BDQ) and imipenem (IPM) against *M. abscessus* ATCC 19977 WT (A), with CFU-adjusted (B) and unadjusted (C) relative bacterial ATP levels, in CAMHB without Tween 80. These data are from a second biological replicate of the experiment in Fig. 6. The changes in log₁₀ CFU/mL after 3 days of drug exposure relative to Day 0 are presented in panel A. CFU-adjusted ATP levels, indicated by relative light units (RLU)/CFU from samples after 3 days of drug exposure, are presented in panel B; relative ATP levels, not adjusted by CFU counts, are presented in panel C. Black bars indicate the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM + BDQ samples. The number after the IPM abbreviation represents the concentration in µg/mL; for red and gray bars, the BDQ concentration in µg/mL is under each bar. The Day 0 bacterial concentration for panel A was 5.95 log₁₀ CFU/mL. CFU and RLU values are provided in Table S9.




Fig. S5. Relative ATP levels, not adjusted by CFU counts, associated with exposure of *M. abscessus* ATCC 19977 WT (A,C) and OM7 mutant (B,D) to bedaquiline (BDQ) and imipenem (IPM) for 1 day (A,B) or 3 days (C,D) in CAMHB without Tween 80. ATP levels are indicated by relative light units (RLU)/CFU from samples. Black bars represent the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM plus BDQ samples. The number after each drug abbreviation represents the concentration in µg/mL (for gray bars the BDQ concentration in µg/mL is presented under each bar). RLU values are provided in **Table S8**.




Fig. S6. Activity of bedaquiline (BDQ) and imipenem (IPM) against nutrient-starved *M. abscessus* ATCC 19977 WT (A) and OM7 mutant (B), with relative bacterial ATP levels (C,D), in PBS without Tween 80. Bacteria were nutrient-starved in PBS for 14 days prior to drug exposure. The changes in \log_{10} CFU/mL after 7 days of drug exposure relative to Day 0 are presented in panels A and B; CFU-adjusted ATP levels, indicated by relative fluorescence units (RLU)/CFU from samples, after 7 days of drug exposure are presented in panels C and D. Black bars indicate the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM + BDQ samples. The number after the IPM abbreviation represents the concentration in μ g/mL; for red and gray bars, the BDQ concentration in μ g/mL is under each bar. Data after 3 days of drug exposure are presented in **Fig. 7**. RLU/mL (not adjusted for CFUs) for WT and OM7 are presented in **Fig. S7** and **Fig. S8**, respectively. The Day 0 bacterial concentration for panels A and B was 6.25 and 6.29 \log_{10} CFU/mL, respectively. CFU and RLU values are provided in **Table S10**.




Fig. S7. Relative ATP levels, not adjusted by CFU counts, associated with exposure of nutrient-starved *M. abscessus* ATCC 19977 WT to bedaquiline (BDQ) and imipenem (IPM) for 4 hours (A), 1 day (B), 3 days (C), or 7 days (D) in PBS without Tween 80. Bacteria were nutrient-starved in PBS for 14 days prior to drug exposure. ATP levels are indicated by relative light units (RLU)/CFU from samples. Black bars represent the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM plus BDQ samples. The number after each drug abbreviation represents the concentration in $\mu\text{g/mL}$ (for gray bars the BDQ concentration in $\mu\text{g/mL}$ is presented under each bar). RLU values are provided in **Table S10**.




Fig. S8. Relative ATP levels, not adjusted by CFU counts, associated with exposure of nutrient-starved *M. abscessus* OM7 mutant to bedaquiline (BDQ) and imipenem (IPM) for 4 hours (A), 1 day (B), 3 days (C), or 7 days (D) in PBS without Tween 80. Bacteria were nutrient-starved in PBS for 14 days prior to drug exposure. ATP levels are indicated by relative fluorescence units (RLU)/CFU from samples. Black bars represent the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM plus BDQ samples. The number after each drug abbreviation represents the concentration in $\mu\text{g/mL}$ (for gray bars the BDQ concentration in $\mu\text{g/mL}$ is presented under each bar). RLU values are provided in **Table S10**.




Fig. S9. Activity of bedaquiline (BDQ) and imipenem (IPM) against nutrient-starved *M. abscessus* ATCC 19977 WT in PBS with 0.05% Tween 80. Bacteria were nutrient-starved in PBS for 20 days prior to drug exposure. Data are presented for two biological replicates (replicate 1 in panels A and C; and replicate 2 in panels B and D). The changes in log₁₀ CFU/mL after 1 and 4 days of drug exposure relative to Day 0 are presented in panels A/B and C/D, respectively. Black bars indicate the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM + BDQ samples. The number after the IPM abbreviation represents the concentration in µg/mL; for red and gray bars, the BDQ concentration in µg/mL is under each bar. Partial data from replicate 1 after 4 days of drug exposure are presented in **Fig. 8**. The Day 0 bacterial concentration for replicate 1 and 2 was 6.07 and 6.38 log₁₀ CFU/mL, respectively. CFU values are provided in **Table S11**.




Fig. S10. Activity of bedaquiline (BDQ) and imipenem (IPM) against nutrient-starved *M. abscessus* ATCC 19977 WT in PBS without Tween 80 (A) and with 0.05% Tween 80 (B). Bacteria were nutrient-starved in PBS for 20 days prior to drug exposure. Data are presented for two biological replicates (replicate 1 in panels A and C; and replicate 2 in panels B and D). The changes in log₁₀ CFU/mL after 3 days of drug exposure relative to Day 0 are presented. Black bars indicate the no drug control; red bars indicate BDQ only samples; blue bars represent IPM only samples, and gray bars indicate IPM + BDQ samples. The number after the IPM abbreviation represents the concentration in µg/mL; for red and gray bars, the BDQ concentration in µg/mL is under each bar. The Day 0 bacterial concentration for panel A and B was 6.48 and 6.51 log₁₀ CFU/mL, respectively. nd, not determined (samples lost). CFU values are provided in **Table S12**.




Fig. S11. Concentration-ranging activity of bedaquiline (BDQ) (A-C) and imipenem (IPM) (D-F) alone against intracellular (THP-1 cells) *M. abscessus* ATCC 19977 WT. Data are presented for 3 biological replicates: replicate 1, panels A,D; replicate 2, panels B,E; replicate 3, panels C,F. Each data point represents a technical replicate, and the connecting lines pass through the mean values. The [number] after each drug abbreviation represents the concentration in µg/mL. All CFU values are provided in **Table S13**.

Table S1. Bedaquiline-resistant *M. abscessus* laboratory isolates.

<i>M. abscessus</i> isolate	Mor-pho-type	CFZ MIC (µg/ml)		BDQ MIC (µg/ml)		<i>MAB_2299c</i> mutation	<i>MAB_2299c</i> AA change	<i>MAB_4384</i> mutation
		CAMHB	7H9	CAMHB	7H9			
ATCC 19977 WT	WT	0.25	8	0.0625	1	None	None	None
OM1	WT	4	16	0.25	4	19C>T	Q7I	None
OM3	WT	2	16	0.5	4	19C>T	Q7I	None
OM4	Rough	nd	16	nd	4	566G>del	Frameshift	None
OM7	WT	2	16	0.5	4	-18_122del	N-terminal truncation	None

WT, wild type. CFZ, clofazimine. BDQ, bedaquiline. MIC: minimum inhibitory concentration, determined by broth microdilution. CAMHB: cation-adjusted Mueller-Hinton broth; 7H9: Middlebrook 7H9 broth with 10% (v/v) Middlebrook oleic acid-albumin-dextrose-catalase supplement; AA, amino acid; nd, not determined. Tween 80 was not included in either assay medium.

Table S2. CFU data from samples presented in Fig. 1. This table also includes data from replicate assays that are not shown in Fig. 1. Assay medium was CAMHB with 0.05% Tween 80. Red shading indicates bedaquiline (BDQ) samples, and blue shading indicates imipenem (IPM) or IMP with avibactam (AVI) samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:	
		Day 3	Day 7
ATCC 19977 WT, CAMHB + Tween, Day 0 = 5.96 log ₁₀ CFU/mL, Fig. 1A (Day 3 data); Day 7 data not in a figure	No drug	Clump	Clump
	BDQ 0.015625	Clump	Clump
	BDQ 0.03125	Clump	Clump
	BDQ 0.0625	6.58	6.56
	BDQ 0.125	6.27	6.41
	BDQ 0.25	6.02	6.08
	BDQ 0.5	6.04	5.78
	BDQ 1	5.93	5.91
	BDQ 2	5.95	5.30
	BDQ 4	5.92	5.53
	BDQ 8	6.09	5.53
	BDQ 16	6.03	5.30
OM7 mutant, CAMHB + Tween, Day 0 = 6.11 log ₁₀ CFU/mL, Fig. 1B (Day 3 data); Day 7 data not in a figure	No drug	Clump	Clump
	BDQ 0.015625	Clump	Clump
	BDQ 0.03125	Clump	Clump
	BDQ 0.0625	Clump	Clump
	BDQ 0.125	Clump	Clump
	BDQ 0.25	Clump	Clump
	BDQ 0.5	Clump	Clump
	BDQ 1	Clump	Clump
	BDQ 2	5.90	5.95
	BDQ 4	6.10	6.11
	BDQ 8	6.15	5.72
	BDQ 16	5.96	5.72
ATCC 19977 WT, CAMHB + Tween, Day 0 = 5.81 log ₁₀ CFU/mL, Fig. 1C	No drug	Clump	nd
	IPM 0.5	Clump	nd
	IPM 1	6.45	nd
	IPM 2	4.62	nd
	IPM 4	3.17	nd
	IPM 8	3.09	nd
	IPM 16	3.02	nd
	IPM 32	2.81	nd
	IPM 64	2.82	nd
	IPM 128	2.86	nd
ATCC 19977 WT, CAMHB + Tween, Day 0 = 6.20 log ₁₀ CFU/mL, Replicate not in a figure	No drug	Clump	Clump
	IPM 1	6.64	Clump
	IPM 2	6.48	Clump
	IPM 4	6.00	Clump
	IPM 8	4.90	Clump
	IPM 16	4.41	6.85
	IPM 32	3.10	6.03
	IPM 64	3.32	5.41
	IPM 128	3.48	2.51
IPM 256	3.87	1.54	

Table continued on next page.

Table S2, continued.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:	
		Day 3	Day 7
OM7 mutant, CAMHB + Tween, Day 0 = 5.85 log ₁₀ CFU/mL, Fig. 1D	No drug	Clump	nd
	IPM 0.5	Clump	nd
	IPM 1	6.16	nd
	IPM 2	2.33	nd
	IPM 4	1.23	nd
	IPM 8	1.49	nd
	IPM 16	2.17	nd
	IPM 32	1.11	nd
	IPM 64	0.85	nd
	IPM 128	0*	nd
OM7 mutant, CAMHB + Tween, Day 0 = 5.96 log ₁₀ CFU/mL, Replicate not in a figure	No drug	Clump	Clump
	IPM 1	5.60	Clump
	IPM 2	3.00	Clump
	IPM 4	3.00	6.31
	IPM 8	2.30	2.79
	IPM 16	3.58	2.42
	IPM 32	3.14	2.66
	IPM 64	3.35	2.68
	IPM 128	4.15	2.75
	IPM 256	0.85	2.41
ATCC 19977 WT, CAMHB + Tween, Day 0 = 5.81 log ₁₀ CFU/mL, Fig. 1E	No drug	Clump	nd
	AVI 2	Cump	nd
	IPM 0.5 + AVI 2	6.37	nd
	IPM 1 + AVI 2	5.45	nd
	IPM 2 + AVI 2	2.83	nd
	IPM 4 + AVI 2	2.90	nd
	IPM 8 + AVI 2	2.81	nd
	IPM 16 + AVI 2	2.81	nd
	IPM 32 + AVI 2	2.89	nd
	IPM 64 + AVI 2	2.72	nd
IPM 128 + AVI 2	2.66	nd	
OM7 mutant, CAMHB + Tween, Day 0 = 5.85 log ₁₀ CFU/mL, Fig. 1F	No drug	Clump	nd
	AVI 2	Cump	nd
	IPM 0.5 + AVI 2	6.22	nd
	IPM 1 + AVI 2	5.45	nd
	IPM 2 + AVI 2	2.87	nd
	IPM 4 + AVI 2	3.72	nd
	IPM 8 + AVI 2	3.15	nd
	IPM 16 + AVI 2	3.10	nd
	IPM 32 + AVI 2	3.04	nd
	IPM 64 + AVI 2	3.02	nd
IPM 128 + AVI 2	2.78	nd	

"Clump" indicates that the bacteria had overgrown and formed clumps, precluding CFU quantification. nd, not determined.

*Lower limit of detection: 0.48 log₁₀ CFU/mL

Table S3. CFU data from samples presented in Fig. 2. Assay medium was CAMHB with 0.05% Tween 80. Red shading indicates bedaquiline (BDQ) samples, blue shading indicates imipenem (IPM) or IMP with avibactam (AVI) samples, and gray shading indicates IPM + AVI + BDQ samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:	
		Day 3	Day 5
ATCC 19977 WT , CAMHB + Tween, Day 0 = 5.57 log ₁₀ CFU/mL, Fig. 2A (Day 3 data); Day 5 data and data from additional combinations not included in a figure	No drug	Clump	Clump
	BDQ 0.5	5.45	Clump
	BDQ 1	5.30	Clump
	AVI 2	Clump	Clump
	IPM 2	Clump	Clump
	IPM 4	5.26	Clump
	IPM 2 + AVI 2	3.78	Clump
	IPM 4 + AVI 2	3.30	Clump
	IPM 2 + AVI 2 + BDQ 0.00390625	3.60	<3.30*
	IPM 2 + AVI 2 + BDQ 0.015625	5.14	5.56
	IPM 2 + AVI 2 + BDQ 0.0625	5.26	5.03
	IPM 2 + AVI 2 + BDQ 0.25	5.82	5.45
	IPM 2 + AVI 2 + BDQ 0.5	5.88	5.73
	IPM 2 + AVI 2 + BDQ 1	5.99	5.81
	IPM 4 + AVI 2 + BDQ 0.00390625	3.26	Clump
	IPM 4 + AVI 2 + BDQ 0.015625	4.13	Clump
	IPM 4 + AVI 2 + BDQ 0.0625	5.26	Clump
	IPM 4 + AVI 2 + BDQ 0.25	5.66	Clump
	IPM 4 + AVI 2 + BDQ 0.5	5.72	Clump
	IPM 4 + AVI 2 + BDQ 1	5.81	Clump
OM7 mutant , CAMHB + Tween, Day 0 = 5.76 log ₁₀ CFU/mL, Fig. 2B (Day 3 data); Day 5 data and data from additional combinations not included in a figure	No drug	Clump	Clump
	BDQ 0.5	7.06	Clump
	BDQ 1	6.12	Clump
	AVI 2	Clump	Clump
	IPM 2	6.18	Clump
	IPM 4	5.08	Clump
	IPM 2 + AVI 2	3.60	Clump
	IPM 4 + AVI 2	4.00	Clump
	IPM 2 + AVI 2 + BDQ 0.00390625	2.78	5.58
	IPM 2 + AVI 2 + BDQ 0.015625	3.20	5.56
	IPM 2 + AVI 2 + BDQ 0.0625	4.89	Clump
	IPM 2 + AVI 2 + BDQ 0.25	5.45	Clump
	IPM 2 + AVI 2 + BDQ 0.5	5.90	Clump
	IPM 2 + AVI 2 + BDQ 1	5.75	Clump
	IPM 4 + AVI 2 + BDQ 0.00390625	4.87	4.82
	IPM 4 + AVI 2 + BDQ 0.015625	2.78	4.99
	IPM 4 + AVI 2 + BDQ 0.0625	4.25	6.24
	IPM 4 + AVI 2 + BDQ 0.25	5.30	Clump
	IPM 4 + AVI 2 + BDQ 0.5	5.15	5.64
	IPM 4 + AVI 2 + BDQ 1	5.48	6.66

"Clump" indicates that the bacteria had overgrown and formed clumps, precluding CFU quantification.

*The lower limit of detection for this sample was 3.30 log₁₀ CFU/mL.

Table S4. CFU data from samples presented in Fig. S2. Assay medium was CAMHB with 0.05% Tween 80. Gray shading indicates imipenem (IPM) + avibactam (AVI) + bedaquiline (BDQ) samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:	
		Day 3	Day 5
ATCC 19977 WT, CAMHB + Tween, Day 0 = 6.13 log ₁₀ CFU/mL, Fig. S2A (Day 3 data); Day 5 data not included in a figure	No drug	Clump	Clump
	IPM 2 + AVI 2 + BDQ 0.00390625	5.20	7.15
	IPM 2 + AVI 2 + BDQ 0.0078125	5.03	6.45
	IPM 2 + AVI 2 + BDQ 0.015625	4.34	6.79
	IPM 2 + AVI 2 + BDQ 0.03125	5.70	6.56
	IPM 2 + AVI 2 + BDQ 0.0625	5.79	6.30
	IPM 2 + AVI 2 + BDQ 0.125	6.01	6.20
	IPM 2 + AVI 2 + BDQ 0.25	5.89	6.58
	IPM 2 + AVI 2 + BDQ 0.5	5.87	5.76
	IPM 2 + AVI 2 + BDQ 1	5.81	6.34
	IPM 4 + AVI 2 + BDQ 0.00390625	5.16	7.20
	IPM 4 + AVI 2 + BDQ 0.0078125	<3.30*	5.82
	IPM 4 + AVI 2 + BDQ 0.015625	5.11	6.51
	IPM 4 + AVI 2 + BDQ 0.03125	5.23	6.45
	IPM 4 + AVI 2 + BDQ 0.0625	5.62	6.29
	IPM 4 + AVI 2 + BDQ 0.125	5.79	6.87
	IPM 4 + AVI 2 + BDQ 0.25	5.86	5.82
	IPM 4 + AVI 2 + BDQ 0.5	5.81	5.87
	IPM 4 + AVI 2 + BDQ 1	5.89	5.97
OM7 mutant, CAMHB + Tween, Day 0 = 6.22 log ₁₀ CFU/mL, Fig. S2B (Day 3 data); Day 5 data not included in a figure	No drug	Clump	Clump
	IPM 2 + AVI 2 + BDQ 0.00390625	4.60	6.72
	IPM 2 + AVI 2 + BDQ 0.0078125	4.48	6.56
	IPM 2 + AVI 2 + BDQ 0.015625	4.76	6.56
	IPM 2 + AVI 2 + BDQ 0.03125	4.70	6.64
	IPM 2 + AVI 2 + BDQ 0.0625	4.97	6.53
	IPM 2 + AVI 2 + BDQ 0.125	5.51	6.70
	IPM 2 + AVI 2 + BDQ 0.25	5.64	5.94
	IPM 2 + AVI 2 + BDQ 0.5	5.76	6.15
	IPM 2 + AVI 2 + BDQ 1	5.89	5.72
	IPM 4 + AVI 2 + BDQ 0.00390625	3.38	6.70
	IPM 4 + AVI 2 + BDQ 0.0078125	3.15	5.30
	IPM 4 + AVI 2 + BDQ 0.015625	3.00	5.09
	IPM 4 + AVI 2 + BDQ 0.03125	3.70	6.19
	IPM 4 + AVI 2 + BDQ 0.0625	4.41	5.03
	IPM 4 + AVI 2 + BDQ 0.125	5.18	5.27
	IPM 4 + AVI 2 + BDQ 0.25	5.48	5.96
	IPM 4 + AVI 2 + BDQ 0.5	5.53	6.45
	IPM 4 + AVI 2 + BDQ 1	5.72	5.57

"Clump" indicates that the bacteria had overgrown and formed clumps, precluding CFU quantification.

*The lower limit of detection for this sample was 3.30 log₁₀ CFU/mL. The value of 3.30 log₁₀ CFU/mL was used to calculate the change in CFU from Day 0, presented in Fig. S2.

Table S5. CFU data from samples presented in Fig. 3. Assay medium was CAMHB with 0.05% Tween 80. Red shading indicates bedaquiline (BDQ) samples; blue shading indicates meropenem (MEM), MmpL3 inhibitor (MPL), or clarithromycin (CLR) samples; and gray shading indicates BDQ combination samples. MPL is N-4S-methylcyclohexyl-4,6-dimethyl-1H-indole-2-carboxamide.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s)/compound(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:		
		Day 3	Day 5	Day 8
ATCC 19977 WT, CAMHB + Tween, Day 0 = 6.40 log ₁₀ CFU/mL, Fig. 3	No drug	7.59	Clump	Clump
	BDQ 0.00390625	6.77	7.20	6.43
	BDQ 0.015625	7.15	7.67	6.59
	BDQ 0.125	6.41	6.48	5.40
	BDQ 1	5.34	5.36	5.04
	BDQ 4	5.20	5.26	4.85
	MEM 16	3.23	2.48	2.73
	MEM 16 + BDQ 0.00390625	3.98	2.66	4.78
	MEM 16 + BDQ 0.015625	3.76	2.32	4.85
	MEM 16 + BDQ 0.125	5.34	4.95	4.20
	MEM 16 + BDQ 1	3.76	5.15	4.85
	MEM 16 + BDQ 4	5.20	5.00	4.78
	MPL 2	4.11	2.30	1.04
	MPL 2 + BDQ 0.00390625	5.26	2.85	2.38
	MPL 2 + BDQ 0.015625	6.34	5.70	6.48
	MPL 2 + BDQ 0.125	6.15	6.56	6.53
	MPL 2 + BDQ 1	5.40	5.34	5.39
	MPL 2 + BDQ 4	5.43	5.26	5.05
	CLR 4	4.78	3.52	3.27
	CLR 4 + BDQ 0.015625	4.65	3.51	3.20
	CLR 4 + BDQ 0.125	4.90	3.43	2.23
	CLR 4 + BDQ 1	4.91	3.45	1.61
	CLR 4 + BDQ 4	4.79	3.40	1.32

“Clump” indicates that the bacteria had overgrown and formed clumps, precluding CFU quantification.

Table S6. CFU and relative light unit (RLU) data from samples presented in Fig. 4 and Fig. S3. Assay medium was CAMHB with 0.05% Tween 80. Red shading indicates bedaquiline (BDQ) samples, blue shading indicates imipenem (IPM) samples, and gray shading indicates IPM + BDQ samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:		Log ₁₀ RLU/mL at the following time points:		MegaRLU/CFU at the following time points:	
		Day 1	Day 3	Day 1	Day 3	Day 1	Day 3
ATCC 19977 WT, CAMHB + Tween, Day 0 = 6.25 log ₁₀ CFU/mL, Fig. 4A,C; Fig. S3A,C (Replicate 1)	No drug	6.73	7.31	3.28	3.67	356	228
	BDQ 0.0625	6.72	7.24	3.27	3.58	355	217
	BDQ 1	6.68	6.70	2.95	3.17	185	296
	IPM 4	6.12	5.66	3.78	3.61	4576	8945
	IPM 16	4.34	4.51	3.32	3.32	95273	64547
	IPM 4 + BDQ 0.00390625	6.06	5.16	3.84	3.60	5966	27435
	IPM 4 + BDQ 0.0078125	6.32	4.53	3.88	3.63	3648	124618
	IPM 4 + BDQ 0.0625	6.62	6.51	3.74	3.77	1311	1830
	IPM 4 + BDQ 0.25	6.58	6.58	3.24	3.57	461	971
	IPM 4 + BDQ 1	6.78	6.70	2.97	3.24	156	351
	IPM 4 + BDQ 4	6.76	6.75	3.13	3.25	231	319
	IPM 16 + BDQ 0.00390625	4.56	3.48	3.33	3.33	59389	712667
	IPM 16 + BDQ 0.0625	6.11	5.78	3.41	3.41	2026	4322
	IPM 16 + BDQ 0.25	6.66	6.34	3.51	3.51	697	1457
	IPM 16 + BDQ 1	6.62	6.53	3.25	3.25	421	520
ATCC 19977 WT, CAMHB + Tween, Day 0 = 7.03 log ₁₀ CFU/mL, Fig. 4B,D; Fig. S3B,D (Replicate 2)	No drug	7.06	7.42	3.44	3.60	242	152
	BDQ 0.0625	6.79	7.23	3.23	3.44	273	162
	BDQ 1	7.09	7.01	2.52	2.82	27	65
	IPM 4	6.40	5.38	3.69	3.44	1910	11632
	IPM 16	6.21	3.87	3.28	2.97	1169	125338
	IPM 4 + BDQ 0.00390625	6.60	4.83	3.67	3.34	1170	32228
	IPM 4 + BDQ 0.0078125	6.26	5.61	3.64	3.45	2433	6934
	IPM 4 + BDQ 0.0625	6.89	6.79	3.58	3.54	485	556
	IPM 4 + BDQ 0.25	6.89	6.89	3.26	3.27	236	241
	IPM 4 + BDQ 1	7.02	6.91	2.66	2.90	44	96
	IPM 4 + BDQ 4	6.86	6.86	2.53	2.79	47	85
	IPM 16 + BDQ 0.00390625	6.26	4.00	3.32	3.00	1125	100050
	IPM 16 + BDQ 0.0625	6.82	6.45	3.30	3.25	304	630
	IPM 16 + BDQ 0.25	6.97	6.87	3.06	3.18	124	205
	IPM 16 + BDQ 1	7.00	6.83	2.73	2.95	54	131
IPM 16 + BDQ 4	6.92	6.91	2.59	2.87	46	91	

Table S7. CFU data from samples presented in Fig. 5. This table also includes data from replicate assays that are not shown in Fig. 5. Assay medium was CAMHB without Tween 80. Red shading indicates bedaquiline (BDQ) samples, and blue shading indicates imipenem (IPM) samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at Day 3
ATCC 19977 WT, CAMHB (no Tween), Day 0 = 5.90 log ₁₀ CFU/mL, Fig. 5A, with additional concentrations not in the figure	No drug	Clump
	BDQ 0.0078125	Clump
	BDQ 0.015625	6.44
	BDQ 0.03125	5.83
	BDQ 0.0625	5.53
	BDQ 0.125	5.23
	BDQ 0.25	5.25
	BDQ 0.5	5.11
	BDQ 1	5.05
	BDQ 2	5.00
	BDQ 4	5.08
	BDQ 8	5.29
	BDQ 16	5.23
OM7 mutant, CAMHB (no Tween), Day 0 = 5.08 log ₁₀ CFU/mL, Fig. 5B, with additional concentrations not in the figure	No drug	Clump
	BDQ 0.0078125	Clump
	BDQ 0.015625	Clump
	BDQ 0.03125	Clump
	BDQ 0.0625	Clump
	BDQ 0.125	Clump
	BDQ 0.25	Clump
	BDQ 0.5	5.70
	BDQ 1	5.66
	BDQ 2	5.66
	BDQ 4	5.79
	BDQ 8	5.85
	BDQ 16	5.95
ATCC 19977 WT, CAMHB (no Tween), Day 0 = 5.91 log ₁₀ CFU/mL, Fig. 5C	No drug	Clump
	IPM 1	Clump
	IPM 2	Clump
	IPM 4	Clump
	IPM 8	Clump
	IPM 16	6.01
	IPM 32	5.79
	IPM 64	5.62
	IPM 128	5.15
	IPM 256	4.73
ATCC 19977 WT, CAMHB (no Tween), Day 0 = 5.28 log ₁₀ CFU/mL, Replicate not in a figure	No drug	Clump
	IPM 1	Clump
	IPM 2	Clump
	IPM 4	Clump
	IPM 8	Clump
	IPM 16	6.06
	IPM 32	6.12
	IPM 64	5.00
	IPM 128	4.78
IPM 256	4.33	

Table continued on next page.

Table S7, continued.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at Day 3
OM7 mutant, CAMHB (no Tween), Day 0 = 6.20 log ₁₀ CFU/mL, Fig. 5D	No drug	Clump
	IPM 1	6.58
	IPM 2	6.64
	IPM 4	5.91
	IPM 8	5.38
	IPM 16	5.41
	IPM 32	5.45
	IPM 64	5.00
	IPM 128	4.86
	IPM 256	4.62
OM7 mutant, CAMHB (no Tween), Day 0 = 5.72 log ₁₀ CFU/mL, Replicate not in a figure	No drug	Clump
	IPM 1	5.66
	IPM 2	5.22
	IPM 4	5.13
	IPM 8	5.05
	IPM 16	5.21
	IPM 32	3.94
	IPM 64	4.97
	IPM 128	4.51
	IPM 256	4.40

“Clump” indicates that the bacteria had overgrown and formed clumps, precluding CFU quantification.

Table S8. CFU and relative light unit (RLU) data from samples presented in Fig. 6 and Fig. S5. Assay medium was CAMHB without Tween 80. Red shading indicates bedaquiline (BDQ) samples, blue shading indicates imipenem (IPM) samples, and gray shading indicates IPM + BDQ samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at Day 3	Log ₁₀ RLU/mL at the following time points:		MegaRLU/CFU at Day 3
			Day 1	Day 3	
ATCC 19977 WT, CAMHB (no Tween), Day 0 = 5.62 log ₁₀ CFU/mL, Fig. 6A,C; Fig. S5A,C (replicate 1)	No drug	Clump	3.00	4.04	nd
	IPM 4	4.51	3.51	3.85	100211
	IPM 16	4.81	3.43	3.45	42488
	BDQ 0.00390625	Clump	3.20	4.20	nd
	BDQ 0.0078125	Clump	2.63	4.03	nd
	BDQ 0.015625	6.16	2.69	3.62	339
	BDQ 0.03125	5.12	2.32	2.83	1569
	BDQ 0.0625	5.09	2.13	2.10	1092
	BDQ 0.125	5.07	2.25	2.29	1509
	BDQ 0.25	5.26	2.17	3.26	813
	BDQ 0.5	5.03	2.30	2.22	1846
	BDQ 1	4.78	2.11	1.80	2151
	BDQ 4	4.53	2.08	2.83	3506
	IPM 4 + BDQ 0.00390625	5.08	3.31	3.53	16902
	IPM 4 + BDQ 0.0078125	5.09	2.91	3.43	6482
	IPM 4 + BDQ 0.015625	5.16	2.58	3.36	2630
	IPM 4 + BDQ 0.03125	5.26	2.49	3.24	1673
	IPM 4 + BDQ 0.0625	5.22	2.19	2.29	932
	IPM 4 + BDQ 0.125	4.75	2.11	2.80	2307
	IPM 4 + BDQ 0.25	4.87	2.11	2.82	1736
	IPM 4 + BDQ 0.5	4.72	2.09	1.90	2322
	IPM 4 + BDQ 1	4.73	2.09	2.85	2263
	IPM 4 + BDQ 4	4.34	2.24	2.68	7870
	IPM 16 + BDQ 0.00390625	5.16	3.01	2.87	7015
	IPM 16 + BDQ 0.0078125	5.09	2.76	2.81	4658
	IPM 16 + BDQ 0.015625	4.99	2.56	2.63	3720
	IPM 16 + BDQ 0.03125	5.28	2.48	2.39	1562
	IPM 16 + BDQ 0.0625	5.33	2.32	2.71	971
	IPM 16 + BDQ 0.125	5.19	2.19	2.02	991
	IPM 16 + BDQ 0.25	4.79	2.37	2.04	3800
IPM 16 + BDQ 0.5	5.66	2.16	2.79	313	
IPM 16 + BDQ 1	4.64	2.34	2.01	4980	
IPM 16 + BDQ 4	4.81	2.17	1.63	2272	

Table continued on next page.

Table S8, continued.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at Day 3	Log ₁₀ RLU/mL at the following time points:		MegaRLU/CFU at Day 3
			Day 1	Day 3	
OM7 mutant, CAMHB (no Tween), Day 0 = 5.70 log ₁₀ CFU/mL, Fig. 6B,D; Fig. S5B,D	No drug	Clump	3.27	3.98	nd
	IPM 4	4.45	3.89	3.83	239354
	IPM 16	3.83	3.63	3.59	566382
	BDQ 0.00390625	Clump	3.38	3.95	nd
	BDQ 0.0078125	Clump	3.27	4.18	nd
	BDQ 0.015625	Clump	2.99	4.12	nd
	BDQ 0.03125	Clump	2.75	4.14	nd
	BDQ 0.0625	6.11	2.21	3.77	4576
	BDQ 0.125	5.30	2.27	4.53	169485
	BDQ 0.25	5.15	2.32	4.43	192156
	BDQ 0.5	5.03	2.14	2.44	2592
	BDQ 1	5.16	2.02	2.52	2289
	BDQ 4	5.02	2.03	2.30	1915
	IPM 4 + BDQ 0.00390625	4.78	3.52	3.65	73657
	IPM 4 + BDQ 0.0078125	5.24	3.27	3.49	17571
	IPM 4 + BDQ 0.015625	5.49	2.95	3.27	6024
	IPM 4 + BDQ 0.03125	5.20	2.71	3.18	9487
	IPM 4 + BDQ 0.0625	5.20	2.55	2.99	6118
	IPM 4 + BDQ 0.125	5.36	2.29	2.75	2417
	IPM 4 + BDQ 0.25	5.20	2.22	2.64	2699
	IPM 4 + BDQ 0.5	4.90	2.23	2.54	4303
	IPM 4 + BDQ 1	4.78	2.16	2.58	6301
	IPM 4 + BDQ 4	5.00	2.30	2.58	3773
	IPM 16 + BDQ 0.00390625	4.60	3.14	3.25	44835
	IPM 16 + BDQ 0.0078125	4.85	2.93	3.12	19020
	IPM 16 + BDQ 0.015625	4.76	2.87	3.04	19084
	IPM 16 + BDQ 0.03125	5.23	2.75	3.01	6047
	IPM 16 + BDQ 0.0625	5.27	2.73	2.82	3577
	IPM 16 + BDQ 0.125	5.13	2.38	2.70	3709
	IPM 16 + BDQ 0.25	5.03	2.29	2.55	3275
	IPM 16 + BDQ 0.5	4.79	2.17	2.50	5090
	IPM 16 + BDQ 1	5.26	2.15	2.47	1616
IPM 16 + BDQ 4	5.01	2.28	2.29	1898	

"Clump" indicates that the bacteria had overgrown and formed clumps, precluding CFU quantification. nd indicates not determined (due to lack of CFU count data).

Table S9. CFU and relative light unit (RLU) data from samples presented in Fig. S4. Assay medium was CAMHB without Tween 80. Red shading indicates bedaquiline (BDQ) samples, blue shading indicates imipenem (IPM) samples, and gray shading indicates IPM + BDQ samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:		Log ₁₀ RLU/mL at the following time points:			MegaRLU/CFU at the following time points:	
		Day 1	Day 3	Hour 4	Day 1	Day 3	Day 1	Day 3
ATCC 19977 WT, CAMHB (no Tween), Day 0 = 5.95 log ₁₀ CFU/mL, Fig. S4 (replicate 2)	No drug	7.01	Clump	1.87	2.90	4.04	77	nd
	IPM 4	5.68	5.29	2.72	3.78	4.11	12490	65650
	IPM 16	5.02	4.68	3.09	3.65	3.66	43291	94145
	BDQ 0.00390625	6.66	Clump	2.38	3.17	3.74	323	nd
	BDQ 0.0078125	6.35	Clump	2.41	3.00	3.93	443	nd
	BDQ 0.015625	5.98	6.41	2.17	2.51	4.05	341	4341
	BDQ 0.03125	5.81	5.78	1.28	2.19	3.38	243	4007
	BDQ 0.0625	5.76	5.76	1.50	2.24	2.42	296	449
	BDQ 0.125	5.70	5.72	1.56	2.06	2.38	231	459
	BDQ 0.25	5.70	5.60	1.95	1.89	2.30	154	502
	BDQ 0.5	5.66	5.34	not detected	1.91	2.24	176	789
	BDQ 1	5.75	5.29	not detected	1.87	2.08	131	613
	BDQ 4	5.58	5.32	not detected	1.64	1.66	114	217
	IPM 4 + BDQ 0.00390625	5.70	5.13	2.53	3.47	3.62	5864	30496
	IPM 4 + BDQ 0.0078125	5.48	5.62	2.69	3.41	3.43	8651	6400
	IPM 4 + BDQ 0.015625	5.76	5.48	2.10	3.01	3.16	1781	4850
	IPM 4 + BDQ 0.03125	5.92	5.68	1.64	2.59	2.94	464	1813
	IPM 4 + BDQ 0.0625	5.66	5.78	2.14	2.32	2.61	455	682
	IPM 4 + BDQ 0.125	5.70	5.60	2.10	2.20	2.44	321	684
	IPM 4 + BDQ 0.25	5.75	5.28	2.21	2.04	2.68	194	2479
	IPM 4 + BDQ 0.5	5.70	5.32	1.73	2.14	2.10	276	606
	IPM 4 + BDQ 1	5.87	5.30	1.70	1.85	2.04	96	545
	IPM 4 + BDQ 4	5.48	5.24	1.30	1.72	1.87	173	427
	IPM 16 + BDQ 0.00390625	5.68	5.53	2.87	3.27	3.30	3859	5841
	IPM 16 + BDQ 0.0078125	5.75	5.51	2.85	3.20	3.14	2839	4351
	IPM 16 + BDQ 0.015625	5.75	5.51	2.54	2.95	2.99	1604	3050
	IPM 16 + BDQ 0.03125	5.81	5.66	1.78	2.73	2.86	833	1558
	IPM 16 + BDQ 0.0625	5.78	5.68	2.05	2.29	2.69	322	1011
IPM 16 + BDQ 0.125	5.64	5.73	1.81	2.02	2.47	240	549	
IPM 16 + BDQ 0.25	5.78	5.56	2.13	2.10	2.36	212	642	
IPM 16 + BDQ 0.5	5.68	5.64	1.73	2.10	2.18	260	347	
IPM 16 + BDQ 1	5.82	5.14	1.61	1.98	2.15	145	1020	
IPM 16 + BDQ 4	5.64	5.09	1.68	1.66	2.02	103	838	

“Clump” indicates that the bacteria had overgrown and formed clumps, precluding CFU quantification. nd indicates not determined (due to lack of CFU count data).

Table S10. CFU and relative fluorescence unit (RLU) data from samples presented in Fig. 7, Fig. S6, Fig. S7, and Fig. S8. Bacteria were nutrient-starved in PBS for 14 days (NS-14) prior to drug exposure. Drug activity assays were performed in PBS without Tween 80. Red shading indicates bedaquiline (BDQ) samples, blue shading indicates imipenem (IPM) samples, and gray shading indicates IPM + BDQ samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:		Log ₁₀ RLU/mL at the following time points:				MegaRLU/CFU at the following time points:	
		Day 3	Day 7	Hour 4	Day 1	Day 3	Day 7	Day 3	Day 7
ATCC 19977 WT, NS-14 (no Tween), Day 0 = 6.25 log ₁₀ CFU/mL, Fig. 7A,C; Fig. S6A,C; Fig. S7	No drug	6.26	6.20	2.44	2.39	2.40	2.58	135	241
	IPM 4	6.12	6.68	2.45	2.47	2.60	2.91	302	170
	IPM 16	6.09	5.95	2.49	2.52	2.65	2.92	357	918
	BDQ 0.00390625	6.23	6.07	2.52	2.44	2.47	2.62	178	355
	BDQ 0.0078125	6.13	6.20	2.45	2.41	2.45	2.63	208	264
	BDQ 0.015625	6.18	6.23	2.48	2.46	2.43	2.62	178	250
	BDQ 0.03125	6.17	6.18	2.37	2.25	2.31	2.48	138	200
	BDQ 0.0625	6.09	6.18	2.34	2.24	2.25	2.46	145	188
	BDQ 0.125	5.90	6.53	2.32	2.18	2.23	2.42	213	78
	BDQ 0.25	5.53	5.36	2.49	2.18	2.20	2.34	471	953
	BDQ 0.5	5.13	4.48	2.34	2.18	2.21	2.31	1182	6752
	BDQ 1	4.16	3.89	2.34	2.20	2.21	2.33	11142	27340
	BDQ 4	2.21	0.95	2.29	2.17	2.18	2.30	938750	25137500
	IPM 4 + BDQ 0.00390625	5.93	6.48	2.44	2.50	2.63	2.84	499	229
	IPM 4 + BDQ 0.0078125	6.28	6.56	2.42	2.47	2.61	2.86	213	203
	IPM 4 + BDQ 0.015625	5.83	6.48	2.38	2.43	2.58	2.88	565	255
	IPM 4 + BDQ 0.03125	6.07	6.38	2.31	2.26	2.33	2.87	183	307
	IPM 4 + BDQ 0.0625	6.00	6.51	2.34	2.25	2.36	2.77	230	186
	IPM 4 + BDQ 0.125	5.93	6.17	2.27	2.21	2.25	2.60	206	270
	IPM 4 + BDQ 0.25	5.64	5.22	2.28	2.18	2.23	2.46	382	1730
	IPM 4 + BDQ 0.5	5.06	4.37	2.33	2.18	2.23	2.34	1450	9322
	IPM 4 + BDQ 1	3.03	4.27	2.35	2.20	2.20	2.22	147685	8750
	IPM 4 + BDQ 4	2.15	2.38	2.32	2.18	2.21	2.21	1158214	675208
	IPM 16 + BDQ 0.00390625	6.24	5.89	2.41	2.50	2.58	2.79	223	782
	IPM 16 + BDQ 0.0078125	6.33	5.76	2.52	2.48	2.54	2.78	163	1051
	IPM 16 + BDQ 0.015625	6.18	5.75	2.33	2.38	2.45	2.66	186	808
	IPM 16 + BDQ 0.03125	5.91	5.93	2.47	2.29	2.41	2.64	311	503
	IPM 16 + BDQ 0.0625	5.91	5.28	2.33	2.22	2.27	2.43	228	1412
	IPM 16 + BDQ 0.125	5.68	5.07	2.27	2.19	2.21	2.39	336	2059
	IPM 16 + BDQ 0.25	5.41	4.86	2.31	2.18	2.25	2.38	679	3347
IPM 16 + BDQ 0.5	4.90	4.48	2.32	2.18	2.22	2.33	2096	7125	
IPM 16 + BDQ 1	3.82	3.70	2.33	2.19	2.17	2.33	22515	42660	
IPM 16 + BDQ 4	1.79	0.95	2.36	2.15	2.19	2.32	2594167	25987500	

Table continued on next page.

Table S10, continued.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:		Log ₁₀ RLU/mL at the following time points:				MegaRLU/CFU at the following time points:	
		Day 3	Day 7	Hour 4	Day 1	Day 3	Day 7	Day 3	Day 7
OM7 mutant, NS-14 (no Tween), Day 0 = 6.29 log ₁₀ CFU/mL, Fig. 7B,D; Fig. S6B,D; Fig. S8	No drug	6.42	6.82	2.30	2.34	2.31	2.52	78	50
	IPM 4	6.43	6.58	2.36	2.47	2.61	2.91	150	215
	IPM 16	6.26	6.12	2.41	2.46	2.51	2.85	174	536
	BDQ 0.00390625	6.31	6.32	2.40	2.45	2.36	2.53	113	162
	BDQ 0.0078125	6.23	6.27	2.35	2.29	2.29	2.48	115	159
	BDQ 0.015625	6.30	5.91	2.48	2.41	2.41	2.58	128	468
	BDQ 0.03125	6.26	6.19	2.35	2.35	2.32	2.52	113	213
	BDQ 0.0625	6.20	6.26	2.30	2.22	2.25	2.43	112	148
	BDQ 0.125	6.15	6.21	2.28	2.14	2.18	2.42	107	161
	BDQ 0.25	6.11	6.03	2.22	2.10	2.09	2.31	95	192
	BDQ 0.5	6.00	6.02	2.21	2.13	2.14	2.35	138	215
	BDQ 1	5.83	5.51	2.22	2.12	2.09	2.24	182	544
	BDQ 4	4.51	3.43	2.23	2.12	2.09	2.19	3838	57854
	IPM 4 + BDQ 0.00390625	6.25	6.25	2.39	2.50	2.56	2.84	206	390
	IPM 4 + BDQ 0.0078125	6.25	6.08	2.37	2.43	2.49	2.87	175	612
	IPM 4 + BDQ 0.015625	6.26	6.56	2.39	2.50	2.53	2.88	188	212
	IPM 4 + BDQ 0.03125	6.25	5.94	2.29	2.42	2.45	2.87	161	838
	IPM 4 + BDQ 0.0625	6.26	6.19	2.29	2.34	2.37	2.77	131	386
	IPM 4 + BDQ 0.125	6.11	6.30	2.25	2.21	2.26	2.60	143	200
	IPM 4 + BDQ 0.25	5.89	6.47	2.21	2.19	2.19	2.46	200	98
	IPM 4 + BDQ 0.5	6.06	6.20	2.20	2.14	2.09	2.34	109	138
	IPM 4 + BDQ 1	5.53	5.26	2.24	2.10	2.09	2.22	359	894
	IPM 4 + BDQ 4	4.86	3.68	2.25	2.11	2.07	2.21	1644	33760
	IPM 16 + BDQ 0.00390625	6.33	6.05	2.38	2.48	2.49	2.88	143	673
	IPM 16 + BDQ 0.0078125	6.12	5.87	2.34	2.44	2.46	2.84	219	936
	IPM 16 + BDQ 0.015625	6.11	5.97	2.39	2.43	2.45	2.76	220	606
	IPM 16 + BDQ 0.03125	6.20	5.79	2.37	2.33	2.38	2.69	153	799
	IPM 16 + BDQ 0.0625	6.09	5.68	2.31	2.26	2.32	2.63	170	880
	IPM 16 + BDQ 0.125	5.81	5.60	2.23	2.19	2.26	2.44	281	693
	IPM 16 + BDQ 0.25	5.86	5.45	2.26	2.21	2.17	2.38	205	851
IPM 16 + BDQ 0.5	5.87	5.16	2.26	2.15	2.18	2.31	202	1401	
IPM 16 + BDQ 1	5.58	4.66	2.21	2.10	2.09	2.23	327	3682	
IPM 16 + BDQ 4	4.89	3.79	2.25	2.19	2.13	2.22	1748	26782	

Table S11. CFU data from samples presented in Fig. 8 and Fig. S9. Bacteria were nutrient-starved in PBS for 20 days (NS-20) prior to drug exposure. Drug activity assays were performed in PBS with 0.05% Tween 80. Red shading indicates bedaquiline (BDQ) samples, blue shading indicates imipenem (IPM) samples, and gray shading indicates IPM + BDQ samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at the following time points:	
		Day 1	Day 4
ATCC 19977 WT, NS-20 + Tween, Day 0 = 6.07 log ₁₀ CFU/mL, Fig. 8; Fig. S9A,C (replicate 1)	No drug	5.68	5.48
	IPM 4	5.33	2.27
	IPM 8	4.26	1.36
	IPM 16	4.60	1.18
	BDQ 0.00390625	5.56	5.96
	BDQ 0.0625	5.37	5.51
	BDQ 1	5.32	5.04
	BDQ 4	5.13	4.66
	IPM 4 + BDQ 0.00390625	5.62	4.26
	IPM 4 + BDQ 0.0625	5.33	4.90
	IPM 4 + BDQ 0.25	5.35	5.23
	IPM 4 + BDQ 1	5.15	4.95
	IPM 4 + BDQ 4	5.08	4.56
	ATCC 19977 WT, NS-20 + Tween, Day 0 = 6.38 log ₁₀ CFU/mL, Fig. S9B,D (replicate 2)	No drug	6.38
IPM 4		5.97	Contam.
IPM 8		5.60	2.08
IPM 16		4.88	0.00
BDQ 0.00390625		6.37	6.22
BDQ 0.0625		5.94	6.21
BDQ 1		6.04	5.89
BDQ 4		6.05	5.37
IPM 4 + BDQ 0.00390625		6.15	5.89
IPM 4 + BDQ 0.0625		6.03	5.94
IPM 4 + BDQ 0.25		6.11	5.56
IPM 4 + BDQ 1		6.06	5.81
IPM 4 + BDQ 4		6.01	5.29

"Contam." indicates that bacterial or fungal contamination precluded assessment of this sample.

Table S12. CFU data from samples presented in Fig. S10. Bacteria were nutrient-starved in PBS for 20 days (NS-20) prior to drug exposure. Drug activity assays were performed in PBS with or without 0.05% Tween 80. Red shading indicates bedaquiline (BDQ) samples; blue shading indicates imipenem (IPM) samples; gray shading indicates IPM + BDQ samples.

Strain, condition, Day 0 bacterial burden, figure number	Drug(s) and concentration(s) in µg/mL	Log ₁₀ CFU/mL at Day 3
ATCC 19977 WT, NS-20 (no Tween), Day 0 = 6.48 log ₁₀ CFU/mL, Fig. S10A	No drug	6.29
	IPM 2	6.32
	IPM 4	6.47
	IPM 8	6.43
	IPM 16	6.48
	IPM 64	6.02
	BDQ 0.00390625	6.56
	BDQ 0.015625	6.07
	BDQ 0.0625	5.88
	BDQ 1	4.75
	BDQ 4	4.66
	IPM 4 + BDQ 0.00390625	6.06
	IPM 4 + BDQ 0.0625	6.11
	IPM 4 + BDQ 0.25	5.82
	IPM 4 + BDQ 1	4.89
	IPM 4 + BDQ 4	4.38
	IPM 16 + BDQ 0.00390625	6.32
	IPM 16 + BDQ 0.0625	5.62
	IPM 16 + BDQ 0.25	5.58
	IPM 16 + BDQ 1	4.86
IPM 16 + BDQ 4	4.08	
ATCC 19977 WT, NS-20 + Tween, Day 0 = 6.51 log ₁₀ CFU/mL, Fig. S10B	No drug	6.45
	IPM 4	nd
	IPM 16	nd
	BDQ 0.00390625	6.66
	BDQ 0.015625	6.48
	BDQ 0.0625	6.36
	BDQ 1	6.02
	BDQ 4	5.72
	IPM 4 + BDQ 0.00390625	6.32
	IPM 4 + BDQ 0.0625	6.23
	IPM 4 + BDQ 0.25	6.29
	IPM 4 + BDQ 1	5.98
	IPM 4 + BDQ 4	5.79
	IPM 16 + BDQ 0.00390625	4.41
	IPM 16 + BDQ 0.0625	4.76
	IPM 16 + BDQ 0.25	5.70
IPM 16 + BDQ 1	6.24	
IPM 16 + BDQ 4	5.78	

nd, not determined (samples lost).

Table S13. CFU data from intracellular samples presented in Fig. 9 and Fig. S11. Within each biological replicate, data from up to 3 technical replicates were acquired for each group at each time point. Red shading indicates bedaquiline (BDQ) samples; blue shading indicates imipenem (IPM) samples; gray shading indicates IPM + BDQ samples.

Strain, condition, replicate, figure number	Drug(s) and concentration(s) in µg/mL	Technical replicate	Intracellular log ₁₀ CFU/mL at		
			Day 0	Day 3	Day 5
ATCC 19977 WT, Intracellular (THP-1 cells) assay with MOI 1:10, Biological replicate 1, Fig. 9A; Fig. S11A,D	No drug	1	4.06	6.58	7.19
		2	4.03	6.62	6.97
		3	4.11	6.78	6.96
	BDQ 0.25	1	---	5.34	6.93
		2	---	5.41	6.86
		3	---	5.64	7.10
	BDQ 1	1	---	4.64	5.15
		2	---	4.34	5.38
		3	---	4.64	5.35
	BDQ 4	1	---	---	3.11
		2	---	3.53	3.61
		3	---	3.15	3.11
	BDQ 16	1	---	3.23	2.15
		2	---	2.94	1.90
		3	---	---	1.04
	IPM 8	1	---	4.79	5.00
		2	---	5.25	5.33
		3	---	5.09	5.10
	IPM 16	1	---	4.51	4.38
		2	---	4.64	4.30
		3	---	---	4.26
	IPM 32	1	---	---	4.00
		2	---	4.53	4.24
		3	---	---	4.09
IPM 64	1	---	---	3.85	
	2	---	4.18	3.82	
	3	---	---	3.78	
IPM 32 + BDQ 1	1	---	3.90	---	
	2	---	3.75	2.92	
	3	---	3.42	---	
IPM 64 + BDQ 1	1	---	3.73	---	
	2	---	3.56	---	
	3	---	3.89	2.73	
ATCC 19977 WT, Intracellular (THP-1 cells) assay with MOI 1:10, Biological replicate 2, Fig. 9B; Fig. S11B,E; plus additional combination data not in a figure	No drug	1	3.82	4.96	6.93
		2	3.90	4.89	6.73
		3	3.76	5.03	6.76
	BDQ 0.25	1	---	4.01	---
		2	---	4.30	---
		3	---	---	---
	BDQ 0.5	1	---	3.27	4.41
		2	---	3.54	4.49
		3	---	---	4.47
	BDQ 1	1	---	2.72	3.97
		2	---	2.92	4.10
		3	---	2.90	4.28
	IPM 8	1	---	4.02	3.78
		2	---	3.98	3.89
		3	---	3.92	3.53
	IPM 32	1	---	3.51	3.26
		2	---	3.39	3.31
		3	---	3.45	3.12

Table continued on next page.

Table S13, continued

Strain, condition, replicate, figure number	Drug(s) and concentration(s) in µg/mL	Technical replicate	Intracellular log ₁₀ CFU/mL at		
			Day 0	Day 3	Day 5
ATCC 19977 WT, Intracellular (THP-1 cells) assay with MOI 1:10, Biological replicate 2, Fig. 9B; Fig. S11B,E; plus additional combination data not in a figure	IPM 32 + BDQ 0.25	1	---	2.79	---
		2	---	3.01	---
		3	---	2.79	---
	IPM 32 + BDQ 0.5	1	---	3.40	2.75
		2	---	3.45	2.81
		3	---	3.39	2.87
	IPM 32 + BDQ 1	1	---	2.85	2.26
		2	---	2.94	2.23
		3	---	2.86	2.00
ATCC 19977 WT, Intracellular (THP-1 cells) assay with MOI 1:10, Biological replicate 3, Fig. 9c; Fig. S11C,F; plus additional combination data not in a figure	No drug	1	4.03	5.26	5.73
		2	3.97	4.78	6.03
		3	3.83	5.26	---
	BDQ 0.25	1	---	4.90	5.56
		2	---	5.00	5.60
		3	---	4.60	5.58
	BDQ 0.5	1	---	3.76	3.60
		2	---	4.07	3.38
		3	---	4.26	3.42
	BDQ 1	1	---	3.32	2.18
		2	---	3.55	2.27
		3	---	3.20	2.39
	BDQ 4	1	---	2.78	1.28
		2	---	3.11	1.84
		3	---	2.79	1.65
	IPM 8	1	---	4.33	3.34
		2	---	4.20	3.51
		3	---	4.18	3.62
	IPM 16	1	---	2.30	1.83
		2	---	2.34	2.00
		3	---	---	2.05
	IPM 32	1	---	2.00	1.91
		2	---	1.91	1.94
		3	---	1.91	1.84
	IPM 64	1	---	2.00	0.48
		2	---	1.79	1.36
		3	---	---	1.65
	IPM 32 + BDQ 0.25	1	---	2.33	1.74
		2	---	2.54	2.52
		3	---	2.38	1.65
IPM 64 + BDQ 0.5	1	---	2.31	3.20	
	2	---	2.05	---	
	3	---	2.31	3.00	
IPM 32 + BDQ 1	1	---	2.24	---	
	2	---	2.40	1.61	
	3	---	1.83	1.79	
IPM 64 + BDQ 4	1	---	1.83	1.46	
	2	---	1.88	0.85	
	3	---	1.92	1.11	

Table continued on next page.

Table S13, continued

Strain, condition, replicate, figure number	Drug(s) and concentration(s) in µg/mL	Technical replicate	Intracellular log ₁₀ CFU/mL at		
			Day 0	Day 3	Day 5
ATCC 19977 WT, Intracellular (THP-1 cells) assay with MOI 1:1, Biological replicate 4, Data not presented in a figure	No drug	1	5.04	6.79	nd
		2	4.96	6.53	nd
	BDQ 0.0625	1	---	6.62	nd
		2	---	6.56	nd
	BDQ 1	1	---	4.89	nd
		2	---	4.93	nd
	BDQ 2	1	---	4.60	nd
		2	---	4.56	nd
	IPM 8	1	---	5.06	nd
		2	---	5.30	nd
	IPM 16	1	---	5.15	nd
		2	---	5.15	nd
	IPM 32	1	---	4.96	nd
		2	---	5.10	nd
	IPM 32 + BDQ 1	1	---	4.20	nd
		2	---	4.38	nd
		3	---	4.48	nd

--- indicates not applicable (Day 0) or sample lost (Days 3 or 5). nd, not determined.